SAREUM HOLDINGS PLC : CHK1 Update

(AIM: SAR)

15 December 2014

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

CHK1 Update

Sareum (AIM: SAR), the specialist cancer drug discovery and development business, welcomes the announcement released by BACIT ltd ("BACIT") earlier today. For the avoidance of doubt, whilst the relationship between BACIT and the Cancer Research Technology Pioneer Fund ("CPF") will expand, Sareum's 27.5 per cent share of the CHK1 programme will remain unchanged.

Sareum's CEO, Dr Tim Mitchell, commented: "We are pleased to learn that BACIT has chosen to invest in the full CPF cancer portfolio. The CHK1 pre-clinical development programme remains on-track and we look forward to providing further updates in due course".

Sareum Holdings plc
Tim Mitchell	01223 497 700
Sanlam Securities UK Limited (Nomad)
Simon Clements	020 7628 2200
Hybridan LLP (Broker)
Claire Noyce / William Lynne	020 3 713 4581 / 4582
The Communications Portfolio (Media enquiries)
Ariane Comstive [e-mail]	07785 922 354

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SAREUM HOLDINGS PLC via Globenewswire

HUG#1880383